UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): January 24,
2017
Cocrystal Pharma, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-55158
|
|
35-2528215
|
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
1860 Montreal Rd,
Tucker, GA
|
|
30084
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (678) 892-8800
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers; Compensatory
Arrangements of Certain Officers
Curtis Dale, Interim Chief Financial Officer, tendered his
resignation effective immediately on January 24, 2017. The Company
has initiated a search for a qualified replacement.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
Cocrystal
Pharma, Inc.
|
|
|
|
|
|
|
|
Date: January 30,
2017
|
By:
|
/s/ Gary
Wilcox
|
|
|
|
|
Name: Gary
Wilcox
|
|
|
|
|
Title:
Interim CEO
|
|